Insufficient scRNA-seq data for expression of CAMP at single-cell level.
Insufficient scRNA-seq data for expression of CAMP at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 79% | 42.27 | 519 / 653 | 62% | 5.86 | 373 / 605 |
lung | 96% | 194.52 | 557 / 578 | 40% | 1.80 | 467 / 1155 |
breast | 33% | 13.72 | 151 / 459 | 68% | 8.41 | 758 / 1118 |
spleen | 100% | 660.91 | 241 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 3805.09 | 921 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 138.65 | 27 / 29 |
prostate | 38% | 13.76 | 92 / 245 | 24% | 0.52 | 119 / 502 |
bladder | 38% | 11.19 | 8 / 21 | 16% | 1.66 | 82 / 504 |
heart | 53% | 21.32 | 455 / 861 | 0% | 0 | 0 / 0 |
esophagus | 30% | 9.76 | 433 / 1445 | 19% | 0.46 | 35 / 183 |
adipose | 48% | 17.41 | 574 / 1204 | 0% | 0 | 0 / 0 |
skin | 11% | 2.56 | 206 / 1809 | 35% | 1.95 | 165 / 472 |
kidney | 27% | 7.36 | 24 / 89 | 19% | 0.78 | 173 / 901 |
tonsil | 0% | 0 | 0 / 0 | 42% | 3.02 | 19 / 45 |
intestine | 31% | 16.45 | 299 / 966 | 11% | 0.85 | 58 / 527 |
pancreas | 2% | 0.30 | 6 / 328 | 38% | 1.02 | 67 / 178 |
uterus | 6% | 1.59 | 10 / 170 | 33% | 3.24 | 152 / 459 |
liver | 35% | 16.26 | 80 / 226 | 2% | 0.13 | 10 / 406 |
stomach | 20% | 8.69 | 73 / 359 | 13% | 2.98 | 36 / 286 |
blood vessel | 29% | 14.80 | 391 / 1335 | 0% | 0 | 0 / 0 |
ovary | 13% | 3.24 | 24 / 180 | 15% | 1.18 | 66 / 430 |
adrenal gland | 7% | 2.57 | 19 / 258 | 18% | 0.63 | 42 / 230 |
brain | 14% | 4.64 | 383 / 2642 | 11% | 0.90 | 77 / 705 |
muscle | 7% | 1.76 | 55 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0045766 | Biological process | positive regulation of angiogenesis |
GO_0045087 | Biological process | innate immune response |
GO_0019731 | Biological process | antibacterial humoral response |
GO_0050829 | Biological process | defense response to Gram-negative bacterium |
GO_0071224 | Biological process | cellular response to peptidoglycan |
GO_0071347 | Biological process | cellular response to interleukin-1 |
GO_0001934 | Biological process | positive regulation of protein phosphorylation |
GO_0071356 | Biological process | cellular response to tumor necrosis factor |
GO_1990000 | Biological process | amyloid fibril formation |
GO_0050830 | Biological process | defense response to Gram-positive bacterium |
GO_0019835 | Biological process | cytolysis |
GO_0042742 | Biological process | defense response to bacterium |
GO_0071222 | Biological process | cellular response to lipopolysaccharide |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0061844 | Biological process | antimicrobial humoral immune response mediated by antimicrobial peptide |
GO_0002227 | Biological process | innate immune response in mucosa |
GO_0051873 | Biological process | killing by host of symbiont cells |
GO_0042119 | Biological process | neutrophil activation |
GO_0071354 | Biological process | cellular response to interleukin-6 |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0035580 | Cellular component | specific granule lumen |
GO_0070062 | Cellular component | extracellular exosome |
GO_0042581 | Cellular component | specific granule |
GO_1904724 | Cellular component | tertiary granule lumen |
GO_0042995 | Cellular component | cell projection |
GO_0001530 | Molecular function | lipopolysaccharide binding |
GO_0005515 | Molecular function | protein binding |
Gene name | CAMP |
Protein name | Cathelicidin antimicrobial peptide (18 kDa cationic antimicrobial protein) (CAP-18) (hCAP-18) [Cleaved into: Antibacterial peptide FALL-39 (FALL-39 peptide antibiotic); Antibacterial peptide LL-37; Antibacterial peptide KR-20; Antibacterial peptide LL-23; Antibacterial peptide LL-29; Antibacterial peptide KS-30; Antibacterial peptide RK-31; Antibacterial peptide FF-33] Cathelicidin antimicrobial peptide |
Synonyms | FALL39 hCG_18336 HSD26 CAP18 |
Description | FUNCTION: Antimicrobial protein that is an integral component of the innate immune system . Binds to bacterial lipopolysaccharides (LPS) . Acts via neutrophil N-formyl peptide receptors to enhance the release of CXCL2 . Postsecretory processing generates multiple cathelicidin antimicrobial peptides with various lengths which act as a topical antimicrobial defense in sweat on skin . The unprocessed precursor form, cathelicidin antimicrobial peptide, inhibits the growth of Gram-negative E.coli and E.aerogenes with efficiencies comparable to that of the mature peptide LL-37 (in vitro) . .; FUNCTION: [Antibacterial peptide LL-37]: Antimicrobial peptide that is an integral component of the innate immune system . Binds to bacterial lipopolysaccharides (LPS) . Causes membrane permeabilization by forming transmembrane pores (in vitro) . Causes lysis of E.coli . Exhibits antimicrobial activity against Gram-negative bacteria such as P.aeruginosa, S.typhimurium, E.aerogenes, E.coli and P.syringae, Gram-positive bacteria such as L.monocytogenes, S.epidermidis, S.pyogenes and S.aureus, as well as vancomycin-resistant enterococci (in vitro) . Exhibits antimicrobial activity against methicillin-resistant S.aureus, P.mirabilis, and C.albicans in low-salt media, but not in media containing 100 mM NaCl (in vitro) . Forms chiral supramolecular assemblies with quinolone signal (PQS) molecules of P.aeruginosa, which may lead to interference of bacterial quorum signaling and perturbance of bacterial biofilm formation . May form supramolecular fiber-like assemblies on bacterial membranes . Induces cytokine and chemokine production as well as TNF/TNFA and CSF2/GMCSF production in normal human keratinocytes . Exhibits hemolytic activity against red blood cells . .; FUNCTION: [Antibacterial peptide FALL-39]: Exhibits antimicrobial activity against E.coli and B.megaterium (in vitro). .; FUNCTION: [Antibacterial peptide KR-20]: Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintains activity at increased salt condition . Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes . .; FUNCTION: [Antibacterial peptide LL-23]: Poorly active (MIC > 150 uM) against E.coli strain K12 . Is able to induce the pro-inflammatory cytokine TNF/TNFA or the chemokine CCL2/MCP1 . .; FUNCTION: [Antibacterial peptide LL-29]: Moderately antibacterial. .; FUNCTION: [Antibacterial peptide KS-30]: Moderately antibacterial . Acts synergistically with peptides KR-20 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition . Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes . .; FUNCTION: [Antibacterial peptide RK-31]: Acts synergistically with peptides KS-30 and KR-31, killing bacteria such as S.aureus, E.coli and C.albicans at lower concentrations when present together, and maintain activity at increased salt condition . Does not have the ability to stimulate CXCL8/IL8 release from keratinocytes . .; FUNCTION: [Antibacterial peptide FF-33]: Inhibits the growth of E.coli and B.megaterium and exhibits hemolytic activity against human red blood cells. . FUNCTION: Exhibits antimicrobial activity against E.coli and B.megaterium (in vitro). . |
Accessions | J3KNB4 ENST00000296435.2 P49913 ENST00000652295.2 |